Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial

Autor: Sarega Gurudas, Namritha Patrao, Luke Nicholson, Piyali Sen, Jayashree Ramu, Sobha Sivaprasad, Philip Hykin

Publikováno v: JAMA ophthalmology. 140(2)

It is unclear how visual outcomes vary between patterns of macular edema (ME) resolution in eyes with central retinal vein occlusion (CRVO).To assess best-corrected visual acuity (BCVA) outcomes at 100 weeks based on macular fluid resolution patterns

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1d84bfd6a57dd2dcef4cf79ec48628
https://pubmed.ncbi.nlm.nih.gov/34989787

Impact of injection frequency on 5-year real-world visual acuity outcomes of aflibercept therapy for neovascular age-related macular degeneration

Autor: Rajna Rasheed, Praveen J Patel, Sobha Sivaprasad, Ali Lamin, Konstantinos Balaskas, Sarega Gurudas, Namritha Patrao, Deepthy Menon, Naser Ali, Shruti Chandra

Publikováno v: Eye (Lond)

BACKGROUND: To evaluate the impact of injection frequency on yearly visual outcomes of patients treated with intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) over a period of 5 years in a tertiary ophthalmic centre. DE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::affdf625e05e8998d5891c0ae8dcbb82
https://europepmc.org/articles/PMC8026582/

Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema

Autor: Ranjan Rajendram, Mahdi Muwas, Namritha Patrao, Sobha Sivaprasad, C Vazquez-Alfageme, Luke Nicholson, Jayashree Ramu, Philip G Hykin

Publikováno v: Eye. 31:1358-1364

PurposeIntraocular vascular endothelial growth factor (VEGF) levels increases with the severity of diabetic retinopathy. Response of diabetic macular oedema (DMO) to ranibizumab is driven by VEGF suppression. We hypothesised that the initial reductio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9cab281df0c57ca2aa34011f0be4304
https://doi.org/10.1038/eye.2017.69

Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial

Autor: Randhir Chavan, S J Aldington, Arevik Ghulakhszian, Roxanne Crosby-Nwaobi, Richard D. Smith, Priya Prakash, Edward Hughes, Geoffrey B. Arden, Debendra N. Sahu, Sarah Walker, Alaistair Denniston, Jackie Sturt, Nirodhini Narendran, Nisha Shah, Abosede Cole, Sobha Sivaprasad, Haralabos Eleftheriadis, Joanna Kelly, Peter H Scanlon, Afsar Jafree, Sheena George, Tatiana Mansour, S Chave, A Dale, Tunde Peto, Namritha Patrao, A Toby Prevost, Ajay Bhatnagar, Joana C. Vasconcelos, Philip Hykin, Douglas Lewin, Gary S. Rubin, Chris Hogg, Caroline Murphy, Gilli Vafidis, Maria Sandinha, Frank Ahfat, Geeta Menon, David P. Crabb, Catherine A Egan, Gillian Hood, Joanathan Gibson, Graham A. Hitman, Ian Grierson, Helen Holmes, Deepthy Menon, Lauren Leitch-Devlin

Publikováno v: Sivaprasad, S, Vasconcelos, J C, Prevost, A T, Holmes, H, Hykin, P, George, S, Murphy, C, Kelly, J, Arden, G B, CLEOPATRA Study Group & Peto, T 2018, ' Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial ', The lancet. Diabetes & endocrinology . https://doi.org/10.1016/S2213-8587(18)30036-6
The Lancet. Diabetes & Endocrinology

BACKGROUND: We aimed to assess 24-month outcomes of wearing an organic light-emitting sleep mask as an intervention to treat and prevent progression of non-central diabetic macular oedema.METHODS: CLEOPATRA was a phase 3, single-blind, parallel-group

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da900962587753965c9a5f4b04bd3ca1
http://hdl.handle.net/10044/1/71846

Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data

Autor: Sobha Sivaprasad, Philip Hykin, R Rajendram, M Santarelli, Luke Nicholson, Namritha Patrao, Marta Zola, Irini Chatziralli

Publikováno v: Eye (London, England). 31(11)

PurposeTo determine the average time-point at which it is best to define 'sub-optimal response' after ranibizumab treatment for diabetic macular edema (DME) based on the data obtained from real-life clinical practice.MethodsIn this retrospective obse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::163cc6ed5175175c505cc1b498d68f78
https://pubmed.ncbi.nlm.nih.gov/28622321